Analyzing plasma samples, scientists discovered a new method to separate Alzheimer’s Disease from other dementias via a blood test – the review of the research article by the BIOMEDICA CRO team
A new blood test can track and follow the neurodegeneration in Alzheimer’s Disease (AD) – and exclude other dementias. That is an innovation now presented by researchers at the University of Gothenburg, together with colleagues in Italy and USA.
The new brain-derived tau (BD-tau) assay showed robust and stable technical performances in blood. Thanks to a collaboration between Italy, USA, and Sweden, they measured BD-tau levels in blood samples from 609 patients. Clinically, there were strong correlations between BD-tau levels in blood samples and CSF, indicating that the assay was measuring brain tau.
From a research perspective, BD-tau will be helpful in understanding neurodegenerative processes in Alzheimer’s Disease and how these differ from those in other dementias. From a clinical perspective, BD-tau could easily be implemented as a quick and accessible blood test to diagnose and monitor disease progression in patients with AD.
Please find more information on the University of Gothenburg website, news, “New blood test differentiates neurodegeneration in Alzheimer’s disease from other dementias”.
Alzheimer’s Disease biospecimens by BIOMEDICA CRO – we collect blood samples and associated data for your research work
At BIOMEDICA CRO we propose a prospective and retrospective collection of the numerous human biospecimen types and associated clinical data since 2017. We can provide specimens from Alzheimer’s Disease patients and donors with other neurological disorders, such as:
• Mild Cognitive Impairments (MCI);
• Multiple Sclerosis;
• Alzheimer’s Disease;
• Schizophrenia;
• Anxiety;
• Panic Disorders;
• Post-traumatic Stress Syndrome;
• Healthy control group – age-gender-BMI matched to diseased patients, etc.
Also, we have contracted 50+ clinical sites that allow us to recruit subjects from oncological and other departments.
In addition to human biospecimens, we can obtain precise clinical data, laboratory test results and other valuable information from each donor.
BIOMEDICA CRO operates within the strictest ethical guidelines.
It means that all clinical materials are exclusively obtained after approval of the Institutional Review Board or the Independent Ethical Committee (IRB/IEC). Furthermore, all donors are mandatory consented and signed the Individual Consent Form (ICF).
We are honored to help investigators conduct pre-clinical trials and biomarker discovery by supplying human samples. Our team will be happy to start our cooperation once you need an additional source of high-quality specimens for your research.
The biospecimens procurement process is easy with us! Please email us to start our collaboration: office@biomedica-cro.com / LinkedIn.
